Aesku.Diagnostics GmbH, a leading name in the diagnostics industry, is headquartered in Germany and operates extensively across Europe and beyond. Founded in 2009, the company has established itself as a pioneer in the development of innovative diagnostic solutions, particularly in the fields of autoimmune diseases and infectious diseases. Aesku.Diagnostics offers a range of unique products, including advanced immunoassays and molecular diagnostics, which are distinguished by their accuracy and reliability. The company’s commitment to research and development has led to significant milestones, positioning it as a trusted partner for laboratories and healthcare providers. With a strong market presence, Aesku.Diagnostics is recognised for its contributions to improving patient outcomes through cutting-edge technology and exceptional service. The company continues to drive advancements in diagnostics, ensuring it remains at the forefront of the industry.
How does Aesku.Diagnostics GmbH's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Aesku.Diagnostics GmbH's score of 20 is lower than 84% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Aesku.Diagnostics GmbH, headquartered in Germany, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. This lack of emissions data and commitments suggests that Aesku.Diagnostics may not yet have established a formal framework for measuring or reducing its carbon footprint. In the context of the industry, many organisations are increasingly adopting science-based targets and sustainability initiatives to mitigate climate impact. However, without specific commitments or data, Aesku.Diagnostics GmbH's position on climate action remains unclear.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Aesku.Diagnostics GmbH has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

